These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31977390)

  • 1. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
    Kinsey EN; Zhang T; Armstrong AJ
    Cancer J; 2020; 26(1):64-75. PubMed ID: 31977388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
    Tsao PA; Caram MEV
    Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
    Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
    Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C; Ohlmann CH
    Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
    Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
    Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
    Xu L; Pachynski RK
    Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New treatments for castration-resistant prostate cancer].
    Sautois B; Gennigens C
    Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.
    Mansourian M; Ghasemi Ms K; Khorsandi PhD D; Vaseghi G
    Am J Ther; 2020; 27(5):e541-e543. PubMed ID: 31107252
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Ranasinghe WKB; Reichard CA; Chapin BF
    Eur Urol; 2019 Nov; 76(5):543-545. PubMed ID: 31248604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.